Review of Pharmacology - 9E (2015)

Review of Pharmacology
Cardiovascular System
32. Which of the following statements about the use of
b-adrenergic blockers in CHF is true?
(a) They are first choice drugs for treatment of
decompensated heart failure
(b) They are used as alternative to conventional therapy
with ACE inhibitors ± digitalis/diuretic
(c) They are most useful in stable patients with mild to
moderate heart failure
(d) They should be used at highest possible dose
33. All of the following drugs are useful for long-term
treatment of congestive heart failure except:
(a) Digoxin
(b) Ramipril
(c) Dobutamine
(d) Spironolactone
34. Which of the following drugs is beneficial in a
refractory congestive heart failure by increasing cardiac
contractility and decreasing preload and afterload?
(a) Amiloride
(b) Amiodarone
(c) Amrinone
(d) Carvedilol
35. All of the following statements about the use of spironolactone
in CHF are true except:
(a) It should be administered in low doses to prevent
hyperkalemia
(b) It affords prognostic benefit in severe heart failure
over and above that afforded by ACE inhibitors
(c) It helps to overcome the refractoriness to thiazides
(d) It affords rapid symptomatic relief in CHF patients
36. Current therapeutic status of milrinone in CHF is:
(a) First choice drug for a patient of mild CHF
(b) As an add on drug to tide over the crisis in refractory
CHF
(c) Best drug for long-term maintenance therapy of CHF
(d) Used only to suppress digitalis induced arrhythmias
37. Which of these drugs DO NOT decrease angiotensin II
activity:
(a) Enalapril
(b) Valsartan
(c) Nesiritide
(d) Omapatrilat
38. Which of the following is NOT true about the use of
β blockers in CHF?
(a) These should be started at very low dose and slowly
titrated upwards
(b) Carvedilol is most widely used b blocker
(c) These are drug of choice in acute decompensated
heart failure
(d) These can reduce mortality in CHF patients
39. Mechanism of action of digitalis in atrial fibrillation is:
(a) By decreasing cardiac contractility
(b) Na + K + ATPase inhibition
(c) Increase in refractoriness of AV nodal tissue
(d) By causing bradycardia
40. Which of the following is not given in acute severe
digitalis toxicity?
(a) Potassium
(b) Digibind
(c) Lignocaine
(d) None of these
41. A patient Vipin has been taking digoxin for several
years and is about to receive atropine for some other
indication. A common side effect of digoxin that can be
blocked by atropine is:
(a) Decreased appetite
(b) Increased cardiac contractility
(c) Increased PR interval on the ECG
(d) Tachycardia
42. Digoxin is used in CHF associated with: (DPG 2010)
(a) HOCM (Hypertrophic obstructive cardiomyopathy)
(b) High output failure
(c) Atrial fibrillation with high ventricular rate
(d) All of the above
43. Digoxin is contra indicated in: (RJ 2006)
(a) Supraventricular tachycardia
(b) Atrial fibrillation
(c) Congestive heart failure
(d) Hypertrophic obstructive cardiomyopathy
44. Which one of the following provides hemodynamic
stability and prolongs survival in congestive heart failure?
(Karnataka 2009)
(a) Lisinopril
(b) Furosemide
(c) Digoxin
(d) Milrinone
45. The drug that is NOT useful in congestive heart failure
is: (Karnataka 2009)
(a) Adrenaline
(b) Digoxin
(c) Hydrochlorothiazide
(d) Enalapril
46. Which of the following is not a contraindication for use
of digitalis: (DPG 2006)
(a) Acute rheumatic carditis
(b) Thyrotoxicosis
(c) WPW syndrome
(d) Hyperkalemia
47. Therapeutic plasma level of digoxin is: (DPG 2005)
(a) 0.1-0.3 ng/ml
(b) 0.8-1.5 ng/ml
(c) 1.2 to 2 ng/ml
(d) More than 2.4 ng/ml
48. Digibind is used to: (DPG 2001)
(a) Potentiate the action of digoxin
(b) Decrease the metabolism of digoxin
178
https://kat.cr/user/Blink99/